Keeping shareholders in the loop, page-3

The JPMorgan health conference has been attended every year. If you read the quarterly update issued in January, they said that the dep programs continue to be subject of 'active discussions'.
It's often rinse and repeat isn't it with JF.
As to Viraleze the completion of trial warranted an announcement with an anticipation of releasing results during Q4 23 (25/9/23). By the time of AGM (29/11/23) anticipation had risen to an expectation for results to be reported by Q4 2023.
Another JF play on words and no update to clarify why the miss?
We ended 2022 with a price of 0.55c and end at 0.17c a loss of 69%. Just to get back to 55c will take a rise of 224% or a performance akin to the top mover this year NEU.
Any continuation of the BS as above will not assist. Reset with new CEO (done) and chair by mid year required IMO.
GLTAH.